Mineralys Therapeutics, Inc.
MLYSUnited States
14 filed reports · 161 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
14 reports · Mar 2023 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 11 | 941 | Mar 2023 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 3 | 730 | Dec 2023 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 11, 2026 | 183 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 6, 2026 | 89 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 12, 2026 | 333 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 10, 2025 | 116 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 12, 2025 | 70 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 12, 2025 | 68 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 12, 2025 | 216 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 12, 2024 | 80 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 13, 2024 | 69 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 9, 2024 | 70 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Mar 21, 2024 | 181 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 7, 2023 | 73 | Open |
Financial data
161 concepts · 1,671 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial161 concepts · 1,671 facts · Dec 2021 to Jun 2026
- Accretion amortization of discounts and premiums investments22 · Mar 2022 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value22 · Mar 2022 to Jun 2026
- Allocated share based compensation expense22 · Mar 2022 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents22 · Mar 2022 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect22 · Mar 2022 to Jun 2026
- General and administrative expense (US GAAP)22 · Mar 2022 to Jun 2026
- Increase decrease in accounts payable and accrued liabilities22 · Mar 2022 to Jun 2026
- Increase decrease in accrued interest receivable net22 · Mar 2022 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets22 · Mar 2022 to Jun 2026
- Interest income expense nonoperating net22 · Mar 2022 to Jun 2026
- Net cash provided by used in financing activities22 · Mar 2022 to Jun 2026
- Net cash provided by used in investing activities22 · Mar 2022 to Jun 2026
- Net cash provided by used in operating activities22 · Mar 2022 to Jun 2026
- Net income loss22 · Mar 2022 to Jun 2026
- Nonoperating income expense22 · Mar 2022 to Jun 2026
- Operating expenses (US GAAP)22 · Mar 2022 to Jun 2026
- Operating income loss22 · Mar 2022 to Jun 2026
- Payments to acquire held to maturity securities22 · Mar 2022 to Jun 2026
- Proceeds from maturities prepayments and calls of held to maturity securities22 · Mar 2022 to Jun 2026
- Research and development expense22 · Mar 2022 to Jun 2026
- Share based compensation22 · Mar 2022 to Jun 2026
- Stockholders equity (US GAAP)22 · Mar 2022 to Jun 2026
- Research and development expenses21 · Dec 2022 to Jun 2026
- Common stock par or stated value per share20 · Dec 2022 to Jun 2026
Segments
Figures broken down by business line, region, product or another axis the company reports on.
No segment breakdowns.
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
1 calls · Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 11, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.